Difference between revisions of "Glucarpidase (Voraxaze)"
(Created page with "==General information== Class/mechanism: Recombinant bacterial enzyme that degrades folic acid and antifolates such as methotrexate by hydrolyzing their carboxyl-terminal glutama...") |
|||
| Line 1: | Line 1: | ||
| + | '''FDA approved 1/17/2012''' | ||
==General information== | ==General information== | ||
Class/mechanism: Recombinant bacterial enzyme that degrades folic acid and antifolates such as methotrexate by hydrolyzing their carboxyl-terminal glutamate residues. Glucarpidase catalyzes the degradation of methotrexate to the inactive metabolites 4-deoxy-4-amino-N10-methylpteroic acid (DAMPA) and glutamate.<ref name="insert">[http://www.btgplc.com/document/436 Glucarpidase (Voraxaze) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/glucarpidase.pdf Glucarpidase (Voraxaze) package insert (locally hosted backup)]</ref> | Class/mechanism: Recombinant bacterial enzyme that degrades folic acid and antifolates such as methotrexate by hydrolyzing their carboxyl-terminal glutamate residues. Glucarpidase catalyzes the degradation of methotrexate to the inactive metabolites 4-deoxy-4-amino-N10-methylpteroic acid (DAMPA) and glutamate.<ref name="insert">[http://www.btgplc.com/document/436 Glucarpidase (Voraxaze) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/glucarpidase.pdf Glucarpidase (Voraxaze) package insert (locally hosted backup)]</ref> | ||
Revision as of 19:44, 10 February 2012
FDA approved 1/17/2012
General information
Class/mechanism: Recombinant bacterial enzyme that degrades folic acid and antifolates such as methotrexate by hydrolyzing their carboxyl-terminal glutamate residues. Glucarpidase catalyzes the degradation of methotrexate to the inactive metabolites 4-deoxy-4-amino-N10-methylpteroic acid (DAMPA) and glutamate.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
Brief patient counseling information can be found on the last page of the package insert[1].